KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Bausch Health Companies (BHC) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Bausch Health Companies' Cash & Equivalents rose 8191.93% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 8191.93%. This contributed to the annual value of $1.2 billion for FY2024, which is 2470.96% up from last year.
  • Latest data reveals that Bausch Health Companies reported Cash & Equivalents of $1.3 billion as of Q3 2025, which was up 8191.93% from $1.7 billion recorded in Q2 2025.
  • Bausch Health Companies' 5-year Cash & Equivalents high stood at $1.7 billion for Q2 2025, and its period low was $486.0 million during Q3 2022.
  • For the 5-year period, Bausch Health Companies' Cash & Equivalents averaged around $829.1 million, with its median value being $690.0 million (2021).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 5852.68% in 2023, then soared by 19025.21% in 2025.
  • Bausch Health Companies' Cash & Equivalents (Quarter) stood at $582.0 million in 2021, then dropped by 3.09% to $564.0 million in 2022, then skyrocketed by 67.91% to $947.0 million in 2023, then rose by 24.71% to $1.2 billion in 2024, then rose by 10.75% to $1.3 billion in 2025.
  • Its Cash & Equivalents stands at $1.3 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.1 billion for Q1 2025.